Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A post-marketing study (J-STEP/EL Study)

Journal of Diabetes Investigation

Volumn 8, Issue 6, 2017, Pages 766-775

  Utsunomiya, Kazunori ^a   Shimmoto, Naoki ^b   Senda, Masayuki ^c   Kurihara, Yuji ^b   Gunji, Ryoji ^b   Fujii, Shoko ^b   Kakiuchi, Seigo ^b   Fujiwara, Hisataka ^b   Kameda, Hiroyuki ^c   Tamura, Masahiro ^c   Kaku, Kohei ^d  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KOWA COMPANY LTD   (Japan)

^c Sanofi KK ^*  (Japan)

^d KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Elderly; Sodium glucose transporter 2; Type 2 diabetes mellitus

Indexed keywords

APLEWAY; DEBERZA; GLYCOSYLATED HEMOGLOBIN; TOFOGLIFLOZIN; 6-((4-ETHYLPHENYL)METHYL)-3',4',5',6'-TETRAHYDRO-6'-(HYDROXYMETHYL)SPIRO(ISOBENZOFURAN-1(3H),2'-(2H)PYRAN)-3',4',5'-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; SODIUM GLUCOSE COTRANSPORTER;

ACUTE HEART INFARCTION; ACUTE PYELONEPHRITIS; AGED; ARTICLE; BALANOPOSTHITIS; BODY WEIGHT; BRAIN INFARCTION; BRAIN STEM INFARCTION; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CONSTIPATION; CYSTITIS; DEATH; DEHYDRATION; DERMATITIS; DIABETIC PATIENT; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; ECZEMA; ERYTHEMA; FAINTNESS; FEMALE; FOLLOW UP; GENITAL PRURITUS; GENITAL TRACT INFECTION; HEAT INJURY; HUMAN; HYPOGLYCEMIA; INCIDENCE; INTESTINAL BLEEDING; JAPANESE (PEOPLE); KETOACIDOSIS; LACUNAR STROKE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOCTURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PAPULE; POLLAKISURIA; POLYDIPSIA; POLYURIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; PYELONEPHRITIS; RASH; SEPTIC SHOCK; SIDE EFFECT; SKIN DISEASE; SKIN EXFOLIATION; SWEAT GLAND DISEASE; TREATMENT DURATION; UNCONSCIOUSNESS; URINARY TRACT INFECTION; URTICARIA; VAGINA CANDIDIASIS; VAGINITIS; VULVITIS; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; JAPAN; POSTMARKETING SURVEILLANCE;

AGED; BENZHYDRYL COMPOUNDS; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; JAPAN; MALE; PRODUCT SURVEILLANCE, POSTMARKETING; SODIUM-GLUCOSE TRANSPORT PROTEINS;

EID: 85014568703     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12626     Document Type: Article

References (35)

1. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005; 365: 1333–1346.
2. Tahrani AA, Bailey CJ, Del Prato S, et al. Management of type 2 diabetes: new and future developments in treatment. Lancet 2011; 378: 182–197.
3. Esposito K, Chiodini P, Bellastella G, et al. Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients. Diabetes Obes Metab 2012; 14: 228–233.
4. Bolen S, Tseng E, Hutfless S, et al. Diabetes Medications for Adults With Type 2 Diabetes: An Update. Comparative Effectiveness Reviews, No. 173. Agency for Healthcare Research and Quality 2016.
5. Fujita Y, Inagaki N. Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: clinical data and mechanism of action. J Diabetes Investig 2014; 5: 265–275.
6. Basile JN. The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM). J Diabetes Complications 2013; 27: 280–286.
7. DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab 2012; 14: 5–14.
8. List JF, Whaley JM. Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans. Kidney Int Suppl 2011; 120: S20–S27.
9. Ohtake Y, Sato T, Kobayashi T, et al. Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2012; 55: 7828–7840.
10. Suzuki M, Honda K, Fukazawa M, et al. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther 2012; 341: 692–701.
11. Rosenwasser RF, Rosenwasser JN, Sutton D, et al. Tofogliflozin: a highly selective SGLT2 inhibitor for the treatment of type 2 diabetes. Drugs Today (Barc) 2014; 50: 739–745.
12. Pafili K, Papanas N. Tofogliflozin: the road goes ever on. Expert Opin Pharmacother 2014; 15: 1197–1201.
13. Poole RM, Prossler JE. Tofogliflozin: first global approval. Drugs 2014; 74: 939–944.
14. Kaku K, Watada H, Iwamoto Y, et al. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol 2014; 13: 65.
15. Ikeda S, Takano Y, Cynshi O, et al. A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2015; 17: 984–993.
16. Tanizawa Y, Kaku K, Araki E, et al. Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials. Expert Opin Pharmacother 2014; 15: 749–766.
17. Kowa Company, Ltd. Package insert for Deberza 20 mg Tablet (in Japanese). Available from: http://www.pmda.go.jp/PmdaSearch/iyakuDetail/270072_ 3969021F1032_1_06#CONTRAINDICATIONS. Accessed October 3, 2016.
18. Sanofi KK Package insert for Apleway 20 mg Tablet (in Japanese). Available from: http://www.pmda.go.jp/PmdaSearch/iyakuDetail/780069_3969021F1024_1_06# CONTRAINDICATIONS. Accessed October 3, 2016.
19. Tahara A, Takasu T, Yokono M, et al. Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects. J Pharmacol Sci 2016; 130: 159–169.
20. Yabe D, Nishikino R, Kaneko M, et al. Short-term impacts of sodium/glucose co-transporter 2 inhibitors in Japanese clinical practice: considerations for their appropriate use to avoid serious adverse events. Expert Opin Drug Saf 2015; 14: 795–800.
21. Kowa Company, Ltd. Risk management plan for Deberza 20 mg Tablet. December 2015 (in Japanese). Available from: http://www.pmda.go.jp/files/000209090.pdf. Accessed October 3, 2016.
22. Sanofi KK. Risk management plan for Apleway 20 mg Tablet. December 2015 (in Japanese). Available from: http://www.pmda.go.jp/files/000209091.pdf. Accessed October 3, 2016.
23. Utsunomiya K, Shimmoto N, Senda M, et al. Japanese study of tofogliflozin with type 2 diabetes mellitus patients in an observational study of the elderly (J-STEP/EL): a 12-week interim analysis. J Diabetes Investig 2016; 7: 755–763.
24. Maeda K, Katashima R, Ishizawa K, et al. Japanese Physicians' views on drug post-marketing Surveillance. J Clin Med Res 2015; 7: 956–960.
25. Asahina Y, Sugano H, Sugiyama E, et al. Representation of older patients in clinical trials for drug approval in Japan. J Nutr Health Aging 2014; 18: 520–523.
26. Ministry of Health, Labour and Welfare Japan. Summary of Patient Survey 2011. Available from: http://www.mhlw.go.jp/english/database/db-hss/sps_2011.html. Accessed October 3, 2016.
27. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364–1379.
28. Moghissi E. Management of type 2 diabetes mellitus in older patients: current and emerging treatment options. Diabetes Ther 2013; 4: 239–256.
29. Leiter LA, Langslet G, Vijapurkar U, et al. Simultaneous reduction in both HbA1c and body weight with canagliflozin versus glimepiride in patients with type 2 diabetes on metformin. Diabetes Ther 2016; 7: 269–278.
30. Haas B, Eckstein N, Pfeifer V, et al. Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin. Nutr Diabetes 2014; 4: e143.
31. Geerlings S, Fonseca V, Castro-Diaz D, et al. Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract 2014; 103: 373–381.
32. Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 2015; 38: 1638–1642.
33. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm- 2016 executive summary. Endocr Pract 2016; 22: 84–113.
34. Ogawa W, Sakaguchi K. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors. J Diabetes Investig 2016; 7: 135–138.
35. Scheen AJ. Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. Clin Pharmacokinet 2015; 54: 691–708.